US Stock MarketDetailed Quotes
CVM CEL-SCI
- 1.080
- -0.010-0.92%
Close Oct 4 16:00 ET
- 1.080
- 0.0000.00%
Post 19:50 ET
66.41MMarket Cap-1862P/E (TTM)
1.110High1.050Low210.46KVolume1.110Open1.090Pre Close224.99KTurnover0.35%Turnover RatioLossP/E (Static)61.49MShares3.23052wk High7.83P/B64.46MFloat Cap1.02052wk Low--Dividend TTM59.69MShs Float2499.999Historical High--Div YieldTTM5.51%Amplitude0.817Historical Low1.069Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
CEL-SCI Stock Forum
4 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
As a clinical research organization (CRO) Ergomed has a strong track record with CEL-SCI in fast enrolment and high quality study delivery
CEL-SCI Corporation (NYSE:CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirm...
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
CEL-SCI (NYSE American: CVM) reported new data from its Phase 3 study of Multikine® at the ESMO 2024 Congress. The data shows that Multikine increased the 5-year survival rate to 82.6% in locally advanced resectable head and neck cancer patients deemed low risk for recurrence, compared ...
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
CEL-SCI (NYSE American: CVM)announced it will present new data from its Phase 3 study of Multikine at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. The poster, titled 'Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma...
Head and neck cancers (HNC) remain a global health challenge, impacting thousands of individuals each year. Advances in immunotherapy have offered new hope for improving patient outcomes, particularly concerning survival rates. In this context...
No comment yet